A Phase II Clinical Study of SHR3680 Combined With SHR3162 in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone and Docetaxel
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Fuzuloparib (Primary) ; Rezvilutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 12 May 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2019 New trial record